Orion Infusion Limited

ORIONINFU

BD0472ORINF6

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
633 ^BDT	-1.91%		+19.75%	+75.20%

Feb. 07	Orion Infusion Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Orion Infusion Limited Recommends Cash Dividend for the Year Ended June 30, 2023	CI

Orion Infusion Limited Recommends Cash Dividend for Year Ended on June 30, 2018

November 01, 2018 at 07:05 am EDT

Orion Infusion Limited Board of Directors has recommended 14% cash dividend for the year ended on June 30, 2018.

Latest news about Orion Infusion Limited

Orion Infusion Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 06	CI
Orion Infusion Limited Recommends Cash Dividend for the Year Ended June 30, 2023	Nov. 05	CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	23-10-29	CI
Orion Infusion Limited Announces Executive Changes	23-10-02	CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-02	CI
Orion Infusion Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-03-29	CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-26	CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-04-29	CI
Orion Infusion Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-05	CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-16	CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-07-04	CI
Orion Infusion Limited Recommends Cash Dividend for Year Ended on June 30, 2020	20-11-09	CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2020	20-10-29	CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-04-29	CI
Orion Infusion Limited Reports Earnings Results for the Second Quarter Ended December 31, 2019	20-01-29	CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-15	CI
Orion Infusion Limited Recommends Cash Dividend for Year Ended on June 30, 2019	19-10-27	CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter Ended March 31, 2019	19-05-06	CI
Orion Infusion Limited Reports Earnings Results for the Second Quarter Ended December 31, 2018	19-02-02	CI
Orion Infusion Limited Recommends Cash Dividend for Year Ended on June 30, 2018	18-11-01	CI
Orion Infusion Limited Announces Earnings Results for the Year Ended on June 30, 2018	18-11-01	CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2018	18-10-29	CI
Orion Infusion Limited Announces Un-Audited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2018	18-04-29	CI
Orion Infusion Limited Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended December, 2017	18-01-29	CI
Orion Infusion Limited Reports Unaudited Earnings Results for the First Quarter Ended September 30, 2017	17-11-14	CI

Orion Infusion Limited is a Bangladesh-based large volume parenteral (LVP) manufacturing company. The Company is a provider of quality medicines and health care services through approximately 28 brands and 42 presentations of various formulations. The Company is engaged in manufacturing and marketing of Intravenous (I.V.) fluid, lifesaving intravenous medicine and intravascular saline, which include fluid and nutrient, fluid and electrolyte, fat emulsion for I.V. use, fluid, nutrient and electrolyte, plasma substitute, antiulcerant, osmotic diuretic and amino acid solutions. The Company has the manufacturing facilities for the production of I.V. Rehydration Solutions, Electrolyte Solutions, and Solution for Acidosis, Ranitidine I.V. infusion, Anti-Microbial products viz. Ciprofloxacin I.V., Metronidazole I.V. and others. The Company's production plant is situated at Maikuli, P.S. Rupganj, and District- Naraynganj, Bangladesh.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORION INFUSION LIMITED	+75.20%	117M
ELI LILLY AND COMPANY	+33.25%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.55%	348B
MERCK & CO., INC.	+18.16%	327B
ABBVIE INC.	+4.36%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.69%	147B